Enanta Pharmaceuticals (NASDAQ:ENTA) Earns “Buy” Rating from HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $18.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 207.17% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. JMP Securities restated a “market outperform” rating and set a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird reduced their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Trading Up 4.8 %

Shares of ENTA opened at $5.86 on Tuesday. The company’s 50-day moving average price is $5.80 and its 200 day moving average price is $9.54. Enanta Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $17.80. The firm has a market cap of $124.99 million, a P/E ratio of -1.07 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Equities research analysts forecast that Enanta Pharmaceuticals will post -5.05 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Jay R. Luly bought 45,000 shares of the stock in a transaction that occurred on Wednesday, February 12th. The stock was purchased at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the completion of the purchase, the chief executive officer now owns 846,638 shares in the company, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 13.89% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. US Bancorp DE increased its holdings in shares of Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 4,243 shares during the last quarter. Quest Partners LLC increased its stake in Enanta Pharmaceuticals by 65.0% in the third quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 7,535 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Enanta Pharmaceuticals during the third quarter worth approximately $122,000. Valence8 US LP purchased a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $207,000. Finally, FMR LLC lifted its position in shares of Enanta Pharmaceuticals by 18.9% during the 3rd quarter. FMR LLC now owns 49,301 shares of the biotechnology company’s stock worth $511,000 after buying an additional 7,839 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.